|
US2015093402A1
|
|
Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE
|
|
WO2010088393A2
|
|
Li-kay hybrid peptides that modulate the immune response to influenza
|
|
WO2010027973A1
|
|
Human papillomavirus / li-key hybrids and methods of use
|
|
CA2680600A1
|
|
Li-rnai involved li suppression in cancer immunotherapy
|
|
US2009060936A1
|
|
Ii-key/Her-2/neu hybrid cancer vaccine
|
|
EP2081591A2
|
|
Li-key enhanced vaccine potency
|
|
CA2593779A1
|
|
Li-key/antigenic epitope hybrid peptide vaccines
|
|
WO2006073625A2
|
|
Inhibition of li expression in mammalian cells
|
|
EP1556072A2
|
|
Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
|
|
US2004058881A1
|
|
Ii-Key/antigenic epitope hybrid peptide vaccines
|
|
US2003235594A1
|
|
Ii-Key/antigenic epitope hybrid peptide vaccines
|
|
US2003198626A1
|
|
Inhibition of Ii expression in mammalian cells
|
|
US6432409B1
|
|
Hybrid peptides modulate the immune response
|
|
US6368855B1
|
|
MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
|
|
AU3307497A
|
|
Immunotherapy by modulation of antigen presentation
|
|
US5679527A
|
|
Modification of polypeptide structure
|
|
CA2614785A1
|
|
Regulation of antigen presentation
|
|
WO9426783A1
|
|
Analysis and modification of protein structure
|
|
US5559028A
|
|
Methods of enhancing or antigen presentation to T cells inhibiting
|
